NEURO-BIOTECH CORP. ANNOUNCES, HAVING NOW REACHED DEBT FREE STATUS, AND CURRENTLY PLANNING ITS DISTRIBUTION PROGRAM FOR 2011
BASEL, Switzerland, le 14 déc. /PRNewswire/ - Neuro-Biotech Corp. (PINKSHEET: MRES) (OTCQB: MRES) announced today having now reached debt free status, and currently planning its distribution program for 2011.
After 2 years of hard work and administrative organisation to finance and bring to market the distribution of its products, Neuro-Biotech Corp. is proud to inform its shareholders that it has repaid all debts to third parties totalling the sum of one million, one hundred, twenty five thousand and nine hundred thirteen dollars ($ 1,125,913).
"The team has been working non-stop to attain this level, and we now have all green lights to begin a strategically planned series of Scientific Speakerships and Road Shows in Europe and United States."
For more information on Neuro-Biotech Products: neuro-biotechcorp.com.
Forward Looking Statements
This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company's actual future results or performance may be materially different. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events, or otherwise, could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
SOURCE Neuro-Biotech Corp.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article